title: Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000627:therapeutic use; D000069286:Bortezomib / Q000627:therapeutic use; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D003561:Cytarabine / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics; D010880:Piperidines; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D000069283:Rituximab / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D003561:Cytarabine; C551803:ibrutinib; D000069283:Rituximab; D013792:Thalidomide; C401859:temsirolimus; D000069286:Bortezomib; D000069461:Bendamustine Hydrochloride; D000077269:Lenalidomide; D014740:Vidarabine; D000225:Adenine; C024352:fludarabine; D020123:Sirolimus